Home » Stocks » Orphazyme

Orphazyme A/S (ORPH)

Stock Price: $10.35 USD -0.35 (-3.23%)
Updated Oct 21, 2020 2:50 PM EDT - Market open

Stock Price Chart

Key Info

Market Cap 358.95M
Revenue (ttm) n/a
Net Income (ttm) -64.09M
Shares Out 34.66M
EPS (ttm) -1.85
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 21, 2020
Last Price $10.35
Previous Close $10.69
Change ($) -0.35
Change (%) -3.23%
Day's Open 10.59
Day's Range 10.31 - 10.59
Day's Volume 27,229
52-Week Range 9.51 - 11.07

More Stats

Market Cap 358.95M
Enterprise Value 351.58M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 34.66M
Float n/a
EPS (basic) n/a
EPS (diluted) -1.85
FCF / Share -2.46
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short n/a
Short Ratio n/a
Short % of Float n/a
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 6.78
Revenue n/a
Operating Income -50.14M
Net Income -64.09M
Free Cash Flow -49.19M
Net Cash 7.37M
Net Cash / Share 0.21
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA n/a
ROE n/a
ROIC -1,777.00%
Key stats in USD, based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

*No analysts have provided price targets for this stock.

Financial Performance

Financial numbers in millions DKK.

Financial Overview

Operating Income-336-232
Net Income-337-230
Shares Outstanding20.0019.99
Earnings Per Share-16.87-11.49
Operating Cash Flow-327-235
Capital Expenditures-2.78-0.74
Free Cash Flow-330-236
Cash & Equivalents124395
Total Debt74.23-
Net Cash / Debt49.36395
Book Value52.97388
Numbers in millions DKK, except per-share numbers.

Company Profile

Company Details

Full Name Orphazyme A/S
Country Denmark
Employees 114
CEO Kim Stratton

Stock Information

Ticker Symbol ORPH
Stock Exchange NASDAQ
Sector Health Technology
Industry Pharmaceuticals: Major
Unique Identifier NASDAQ: ORPH
IPO Date September 29, 2020


Orphazyme A/S, a biopharmaceutical company, develops therapies for the treatment of neurodegenerative orphan diseases. The company focuses on developing therapies for diseases caused by misfolding of proteins, including lysosomal storage diseases. Its lead candidate is the Arimoclomol, which is in clinical development for four orphan diseases, including Niemann-Pick disease type C, Gaucher disease, sporadic inclusion body myositis, and amyotrophic lateral sclerosis. The company was founded in 2009 and is headquartered in Copenhagen, Denmark.